NCT01422759

Effect of Spironolactone on Adrenal or Ovarian Androgen Production in Overweight Pubertal Girls With Androgen Excess

Effect of Spironolactone on Adrenal or Ovarian Androgen Production in Overweight Pubertal Girls With Androgen Excess (CBS006)

• Status: Unknown
• Phase: N/A
• Study type: Interventional
• Enrollment: 20 (estimated)
• Sponsor: University of Virginia · Academic / Other
• Sex: Female
• Age: 7 Years – 18 Years
• Healthy volunteers: Not accepted

Summary

Whether 12 weeks of spironolactone can reduce androgen production from ovaries and adrenal glands of girls with obesity and androgen excess

Detailed description

This study will test whether spironolactone administration can ameliorate androgen (male hormone) overproduction in overweight pubertal girls with androgen excess. The investigators hypothesize that reduction in P450c17alpha overactivity and androgen receptor blockade by 12 weeks of spironolactone administration will improve androgen levels after adrenal stimulation testing with adrenocorticotropic hormone (ACTH) and ovarian stimulation testing with recombinant human chorionic gonadotropin (rhCG).

Conditions

• Obesity
• Hyperandrogenemia
• Polycystic Ovary Syndrome

Interventions

Type	Name	Description
DRUG	Spironolactone	50-100 mg PO BID (X 12 weeks)

Timeline

• Start date: 2016-12-09
• Primary completion: 2024-12-01
• Completion: 2024-12-01
• First posted: 2011-08-24
• Last updated: 2023-10-27

Locations

1 site across 1 country: United States